6/29/23, 1:45 AM PRoFESS Pathway Feedback Search Clinical Topics Home Studies PRoFESS PRoFESS Disease Acute ischemic stroke Trial question What is the role of combination of aspirin and ER dipyridamole in patients with a recent stroke? Study design Multi-center Double blinded RCT Population Characteristics of study participants 36.0% female N = 20332 64.0% male 20332 patients (7310 female, 13022 male) Inclusion criteria: patients with a recent ischemic stroke Key exclusion criteria: contraindications to one of the antiplatelet agents, primary hemorrhagic stroke, brain tumor, dementia requiring institutional care, or a mRS score > 4 at baseline Interventions N=10181 ASA-ERDP (aspirin 25 mg plus 200 mg ER dipyridamole BID) N=10151 clopidogrel (75 mg daily) Primary outcome Recurrent stroke 9 9 0 % 8 8 https://web.pathway.md/studies/recEU8B5lCY04pQ98 1/2 6/29/23, 1:45 AM 9.0 % PRoFESS Pathway 9 8.8 6.8 % 4.5 % 2.3 % No significant difference 0.0 % ASA-ERDP Clopidogrel No significant difference in recurrent stroke (9% vs. 8.8%; HR 1.01, 95% CI 0.92 to 1.11) Secondary outcomes No significant difference in stroke, myocardial infarction, or death from vascular causes (13.1% vs. 13.1%; HR 0.99, 99% CI 0.92 to 1.07) No significant difference in recurrent stroke or major hemorrhagic event (11.7% vs. 11.4%; HR 1.03, 95% CI 0.95 to 1.11) No significant difference in myocardial infarction (1.7% vs. 1.9%; HR 0.9, 95% CI 0.73 to 1.1) Safety outcomes No significant differences in frequency of death, any hemorrhagic event, TTP or neutropenia. Significant differences in major hemorrhagic events (4.1% vs. 3.6%), intracranial hemorrhage (1.4% vs. 1.0%). Conclusion In patients with a recent ischemic stroke, ASA-ERDP was not superior to clopidogrel with respect to recurrent stroke. Reference Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. Open reference URL https://web.pathway.md/studies/recEU8B5lCY04pQ98 2/2